Fabry Disease Market Report 2026

The fabry disease market size has grown strongly in recent years. It will grow from $2.26 billion in 2025 to $2.43 billion in 2026 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to increased awareness of rare genetic disorders, approval of enzyme replacement therapies, expansion of specialty clinics, growth in genetic screening programs, rising diagnosis rates.

The fabry disease market size is expected to see strong growth in the next few years. It will grow to $3.27 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to advancement in gene-based therapies, expansion of newborn screening programs, increasing healthcare spending on rare diseases, growth in personalized medicine, development of next-generation oral therapies. Major trends in the forecast period include increasing adoption of enzyme replacement therapy, rising focus on rare disease diagnosis, growing use of genetic testing for early detection, expansion of oral and adjunct therapies, increasing patient-centric treatment approaches.

A growing focus on personalized medicine is expected to propel the growth of the Fabry disease market going forward. Personalized medicine is an approach that uses information about a person’s genes, environment, and lifestyle to tailor medical care and therapies for better outcomes. The rising emphasis on personalized medicine is driven by its ability to improve treatment effectiveness and reduce side effects by customizing therapies to individual patient needs. In Fabry disease, personalized medicine enables treatment plans to be tailored based on a patient’s specific genetic mutation and disease severity, enhancing outcomes while minimizing unnecessary side effects. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, a significant increase from six approvals in 2022. Therefore, the growing focus on personalized medicine is driving the growth of the Fabry disease market.

Major companies operating in the Fabry disease market are focusing on developing innovative therapies, such as PEGylated enzyme replacement therapy (ERT), to enhance treatment efficacy, improve patient compliance, and reduce immunogenic responses associated with conventional ERTs. PEGylated ERT is a modified form of traditional enzyme replacement therapy in which polyethylene glycol (PEG) chains are attached to the enzyme to increase its stability, prolong circulation time in the body, and minimize immune system reactions. For instance, in May 2023, Chiesi Global Rare Diseases, a division of the Chiesi Group, an Italy-based pharmaceutical company, announced U.S. Food and Drug Administration (FDA) approval for PRX-102 (pegunigalsidase alfa) for the treatment of adult Fabry disease patients. The approval is supported by a robust clinical program involving over 140 patients and long-term follow-up of up to 7.5 years, demonstrating the therapy’s efficacy in reducing renal Gb₃ deposits, maintaining kidney function, and exhibiting a favorable safety profile.

In March 2024, Centogene N.V., a US-based rare disease diagnostics company, extended its strategic partnership with Takeda Pharmaceutical Company Limited to continue providing access to genetic testing for patients with lysosomal storage disorders (LSDs). Through this partnership extension, Centogene aims to enhance patient access to rapid and reliable diagnostic testing for LSDs, including Fabry disease, Gaucher disease, and Hunter syndrome, leveraging its multiomic testing portfolio and diagnostic network to accelerate diagnoses and improve health outcomes for underserved rare disease patient communities. Takeda Pharmaceutical Company Limited is a Japan-based biopharmaceutical company specializing in rare disease therapeutics and enzyme replacement therapies, including those for Fabry disease.

Major companies operating in the fabry disease market are Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, JCR Pharmaceuticals Co. Ltd., Sumitomo Pharma Co. Ltd, Chiesi Farmaceutici S.p.A., Amicus Therapeutics Inc., Idorsia Pharmaceuticals Ltd, Sangamo Therapeutics Inc., uniQure N.V., Protalix BioTherapeutics Inc., Spur Therapeutics Inc., Exegenesis Bio Inc., ISU ABXIS Co. Ltd., Eleva GmbH, AceLink Therapeutics Inc., 4D Molecular Therapeutics Inc., iBio Inc., Freeline Therapeutics Holdings plc, Greenovation Biotech GmbH.

North America was the largest region in the fabry disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fabry disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the fabry disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the fabry disease market by increasing the cost of imported biologics, enzyme replacement therapies, and diagnostic reagents used in disease management. These impacts have been most pronounced in hospital and specialty clinic segments in North America and Europe. Asia-Pacific markets have faced supply constraints due to dependence on imported rare disease drugs. However, tariffs have encouraged localized manufacturing and regional distribution partnerships, supporting improved treatment accessibility.

The fabry disease market research report is one of a series of new reports that provides fabry disease market statistics, including fabry disease industry global market size, regional shares, competitors with a fabry disease market share, detailed fabry disease market segments, market trends and opportunities, and any further data you may need to thrive in the fabry disease industry. This fabry disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Fabry disease is a rare genetic disorder caused by a deficiency of the enzyme alpha-galactosidase A, resulting in the accumulation of fat within the body’s cells and organs. Treatment aims to manage symptoms, reduce organ damage, and improve the quality of life for affected individuals.

The main types of Fabry disease include type 1, type 2, and other forms. Type 1 Fabry disease typically begins in childhood and is caused by a near-complete deficiency of alpha-galactosidase A, leading to fat buildup in cells and organs. Treatments include enzyme replacement therapy, oral therapy, adjunct therapies, and other approaches. Diagnosis is performed through blood tests, genetic tests, parenteral tests, and other diagnostic methods. These treatments are distributed via hospital pharmacies, retail pharmacies, and online pharmacies, and are used by hospitals, homecare providers, specialty clinics, and other healthcare facilities.

The fabry disease market consists of revenues earned by entities by providing services such as genetic counseling, patient support programs, clinical trials and research services, and disease monitoring and management services. The market value includes the value of related goods sold by the service provider or contained within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.